A new BMP type 1 receptor kinase inhibitor for safe and efficient oral treatment to prevent genetically induced heterotopic ossification in mice
Bone · 2025
DOI: 10.1016/j.bone.2025.117565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone, 2025. Verfasst von Jingwen Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Lab…. Hauptthemen laut MEDLINE: Ossification, Heterotopic, Protein Kinase Inhibitors, Bone Morphogenetic Protein Receptors, Type I. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NCRR NIH HHS, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School and Hospital of Stomatology, Wuhan Univ…
- Department of Biologic and Materials Sciences & Prosthodontics, University of Michigan School of Dentistry, 1010 N. University Ave, Ann Arbor, MI, 48179, USA.
- Drug Discovery Chemistry Platform Unit, RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan.
- Center for Organogenesis, Regeneration & Trauma, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Division of Plastic Surgery, Brigham and Women's Hospital, Harvard Universi…
- Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan.
- RIKEN Program for Drug Discovery and Medical Technology Platforms, RIKEN TRIP Headquarters, 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan.
Förderung
- NIAMS NIH HHS
- NCRR NIH HHS
- Japan Agency for Medical Research and Development
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- National Center for Research Resources
- School of Dentistry, University of Michigan
- University of Michigan
Zitieren
APA
Yang, J., Pan, H., Sekimata, K., Hwang, C., Kulkarni, A., Thomas, H., Lindenau, J., Duford, T., Ueharu, H., Tanaka, A., Sakai, N., Shirouzu, M., Hashizume, Y., Levi, B., Koyama, H., & Mishina, Y. (2025). A new BMP type 1 receptor kinase inhibitor for safe and efficient oral treatment to prevent genetically induced heterotopic ossification in mice. Bone. https://doi.org/10.1016/j.bone.2025.117565
Vancouver
Yang J, Pan H, Sekimata K, Hwang C, Kulkarni A, Thomas H, et al. A new BMP type 1 receptor kinase inhibitor for safe and efficient oral treatment to prevent genetically induced heterotopic ossification in mice. Bone. 2025. doi:10.1016/j.bone.2025.117565
BibTeX
@article{Yang2025,
author = {Yang, Jingwen and Pan, Haichun and Sekimata, Katsuhiko and Hwang, Charles and Kulkarni, Anshul and Thomas, Hannah and Lindenau, Jade and Duford, Tyler and Ueharu, Hiroki and Tanaka, Akiko and Sakai, Naoki and Shirouzu, Mikako and Hashizume, Yoshinobu and Levi, Benjamin and Koyama, Hiroo and Mishina, Yuji},
title = {A new BMP type 1 receptor kinase inhibitor for safe and efficient oral treatment to prevent genetically induced heterotopic ossification in mice},
journal = {Bone},
year = {2025},
doi = {10.1016/j.bone.2025.117565}
}
EUVIMED